Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07782827
NCT07782827RecruitingPhase 3

Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults With Angelman Syndrome Due to Paternal Uniparental Disomy or Imprinting Defects

Ionis Pharmaceuticals, Inc.1 site in 1 country30 target enrollmentStarted: September 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
30
Locations
1
Primary Endpoint
Change From Baseline in Performance on the Expressive Communication Domain Raw Score Without Caregiver Input of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The primary purpose of the study is to evaluate efficacy of obudanersen in participants with AS due to uniparental disomy or imprinting defects (UPD/ID) as measured through expressive communication.

Detailed Description

This is a Phase 3, open-label, single treatment arm, multi-center study in participants with Angelman syndrome due to paternal uniparental disomy or imprinting defects. The study will consist of 4 periods: a screening period of up to 28 days, an approximate 60-week Treatment Evaluation Period, followed by 101 weeks of Long-Term Extension (LTE) period, and an 8-month Post-Treatment Follow-up Period. There will be two age-based Cohorts enrolled in this study: Cohort 1 (pediatric participants (aged 2 to <18 years old)) and Cohort 2 (adult participants (aged 18 to ≤50 years old). More individuals will be enrolled in Cohort 1 than in Cohort 2.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
2 Years to 50 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Clinical diagnosis of AS with molecular result indicating either paternal UPD of 15q11.2-q13 or ID of the maternal 15q11.2-q13 region, provided by the Investigator and confirmed by either a qualified central vendor or a qualified local geneticist at the site.
  • •The participant's caregiver(s)/legally-authorized representative (LAR) must have given written informed consent and any authorizations required by local law and be able and willing to comply with all study requirements.
  • •Medically stable and can undergo sedation and/or general anesthesia without intubation.
  • •Male or female between 2 and ≤ 50 years of age, depending on the specific cohort, at the time of the in-clinic Screening visit.
  • •If applicable, is currently receiving stable doses of concomitant medications typically prescribed for AS, such as anti-epileptic medication, behavioral management medications, sleep medications, gabapentin, cannabidiol, and special diets, supplements, or nutritional support for at least 8 weeks prior to the Baseline visit. If recent changes (< 8 weeks stable) in medications, the participant may be allowed per Investigator judgment if the change is not expected to have an impact on the signs and symptoms of AS.
  • •LAR/caregiver(s) agree(s) not to post any of the participant's personal medical data or information related to the study on any website or social media site (e.g., Facebook, Instagram, X, YouTube, TikTok, WhatsApp) from the time of enrollment until they are notified that the study is completed.

Exclusion Criteria

  • •Participant has a clinical diagnosis of AS with molecular confirmation of a UBE3A deletion or UBE3A mutation.
  • •Any clinically significant abnormalities in medical history (e.g., major surgery within 3 months of Screening), or on physical examination for which treatment with an antisense oligonucleotide (ASO) would be contraindicated or which, in the opinion of the Investigator, could confound the results of this study.
  • •Known brain or spinal disease that would interfere with the lumbar puncture (LP) procedure, cerebrospinal fluid (CSF) circulation, or presence of other factors that would affect the safety of the LP procedure, including tumors or abnormalities by MRI or computed tomography (CT), subarachnoid hemorrhage, suggestion of raised intracranial pressure (ICP) on magnetic resonance imaging (MRI) or ophthalmic examination, Chiari malformation, obstructive hydrocephalus, syringomyelia, tethered spinal cord syndrome, or connective tissue disorders such as Ehlers-Danlos syndrome and Marfan syndrome.
  • •Any laboratory abnormalities or any other clinically significant abnormalities that would, as assessed by the Investigator, at Screening or Baseline, render a participant unsuitable for inclusion.
  • •Previous treatment with an oligonucleotide (including small interfering ribonucleic acid [siRNA] and ASOs) or gene therapy or gene editing. This exclusion criterion does not apply to approved nucleic acid-based vaccines, including messenger Ribonucleic Acid (mRNA) vaccines, which are allowed.
  • •Other inclusion/exclusion criteria may apply

Arms & Interventions

obudanersen 80 mg

Experimental

Participants in Cohorts 1 and 2 will be administered obudanersen via intrathecal (IT) bolus injection every 12 weeks during the Treatment Evaluation and LTE periods.

Intervention: obudanersen (Drug)

Outcomes

Primary Outcomes

Change From Baseline in Performance on the Expressive Communication Domain Raw Score Without Caregiver Input of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1

Time Frame: Baseline and Week 52

Secondary Outcomes

  • Change From Baseline in Bayley-4: Cognition Scale Raw Score Without Caregiver Input(Baseline and Week 52)
  • Change From Baseline in Aberrant Behavior Checklist - Second Edition - Community Version (ABC-2-C): Hyperactivity(Baseline and Week 52)
  • Change From Baseline in (ABC-2-C): Irritability(Baseline and Week 52)
  • Change From Baseline in Vineland Adaptive Behavior Scale-3 (Vineland-3): Receptive Communication Domain Raw Score(Baseline and Week 52)
  • Change From Baseline in Vineland-3: Daily Living Skills, Personal Domain Raw Score(Baseline and Week 52)
  • Change From Baseline in (Bayley-4): Fine Motor Domain Raw Score Without Caregiver Input(Baseline and Week 52)
  • Change From Baseline in Observer-Reported Communication Ability (ORCA): Overall Emerging and Mastery T Score(Baseline and Week 52)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)Ankylosing Spondylitis
NCT07261644Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.500
Not yet recruiting
Phase 1
IASO206 in Patients With Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma (RRMM)
NCT07322159Institute of Hematology & Blood Diseases Hospital, China12
Recruiting
Phase 1
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic CancerPancreatic Cancer
NCT07444541Anova Innovation Limited84
Recruiting
Phase 1
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung CancerNon-Small Cell Lung Cancer
NCT07538804Avistone Biotechnology Co., Ltd.294
Not yet recruiting
Phase 2
A Phase 2 Study of ABSK043 Combined With OsimertinibNon-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
NCT07710612Abbisko Therapeutics Co, Ltd72